Omeprazol Actavis (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Actavis, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children.

GNH USA supplies Omeprazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to manage several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild, transient headache reported in many patients. - Diarrhea: loose stools that usually resolve without intervention. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmias. - Stevens‑Johnson syndrome: rare skin reaction with blistering and mucosal involvement. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Fracture risk: long‑term use associated with reduced bone mineral density.

Before initiating therapy, consider the following safety measures:

- Assess renal function: adjust use in severe renal impairment. - Evaluate hepatic status: use with caution in moderate liver disease. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term use: assess need for periodic vitamin B12 and magnesium testing. - Pregnancy and lactation: weigh benefits against potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular event risk. - Atazanavir: decreased absorption leading to loss of antiviral efficacy. - Dasatinib: lowered plasma concentrations, potentially reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Phenytoin: reduced serum levels, may necessitate dose adjustment. - Methotrexate: increased exposure, especially at high doses, requiring vigilance. - Digoxin: modest rise in serum concentration, monitor for toxicity signs.